A solid composition for oral administration comprising a GLP-1 derivative and dapagliflozin, wherein said GLP-1 derivative is selected from the group consisting of a. semaglutide, b. N ε26 {2-[2-(2-{2-[2-(2-{ -4-Carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy) ethoxy]acetylamino}ethoxy)ethoxy]acetyl}, N ε37 -{2-[2-(2-{2-[2-(2-{ -4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy] acetylamino}ethoxy)ethoxy]acetyl}-[Aib 8,Arg 34,Lys 37]GLP-1 -peptide c. N ε27 -[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl] amino]ethoxy] ethoxy]acetyl], N ε36 -[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(4-carboxy-phenoxy) decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy] ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys27,Glu30,Arg34,Lys36]-GLP-1- -peptidyl-Glu-Gly d. N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl] amino] ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl],N{Epsilon-37}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36,Lys37]-GLP-1- -peptide e. N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl] amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl],N{Epsilon-37}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Arg26,Arg34,Lys36,Lys37]-GLP-1- -peptide and f. N{Epsilon-36)-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(3-carboxyphenoxy)decanoylamino]butanoyl]amino] ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl],N{Epsilon-37}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(3-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl] amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36,Lys37]-GLP-1- -peptide a. semaglutide, b. N ε26 {2-[2-(2-{2-[2-(2-{ -4-Carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy) ethoxy]acetylamino}ethoxy)ethoxy]acetyl}, N ε37 -{2-[2-(2-{2-[2-(2-{ -4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy] acetylamino}ethoxy)ethoxy]acetyl}-[Aib 8,Arg 34,Lys 37]GLP-1 -peptide c. N ε27 -[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl] amino]ethoxy] ethoxy]acetyl], N ε36 -[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(4-carboxy-phenoxy) decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy] ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys27,Glu30,Arg34,Lys36]-GLP-1- -peptidyl-Glu-Gly d. N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl] amino] ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl],N{Epsilon-37}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36,Lys37]-GLP-1- -peptide e. N{Epsilon-36}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl] amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl],N{Epsilon-37}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butanoyl]amino]ethoxy] ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8,Arg26,Arg34,Lys36,Lys37]-GLP-1- -peptide and f. N{Epsilon-36)-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(3-carboxyphenoxy)decanoylamino]butanoyl]amino] ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl],N{Epsilon-37}-[2-[2-[2-[[2-[2-[2-[[ -4-carboxy-4-[10-(3-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl] amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Arg34,Lys36,Lys37]-GLP-1- -peptide